Latest Sanofi Press Releases and News | Sanofi
WEBSep 20, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
WEB(Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's lung", the ...
Sanofi blockbuster drug wins clearance in US for lung disease
WEB3 days ago · Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after a similar decision by European regulators.
Sanofi Enters Next Chapter of Play to Win Strategy | Sanofi
WEBOct 27, 2005 · Sanofi today provided a comprehensive update regarding its Play to Win strategy. This strategy continues to focus on the critical goals of executing transformative medicine and vaccines launches, driving agile and efficient resource deployment and enhancing R&D productivity.
Press Release: Sanofi and Novavax announce co-exclusive …
WEBMay 10, 2006 · Starting in 2025, Sanofi will book sales of Novavax’s adjuvanted COVID-19 vaccine and will support certain R&D, regulatory, and commercial expenses. Novavax will receive tiered double-digit percentage royalty payments on sales by Sanofi of COVID-19 vaccines and flu-COVID-19 combination vaccines.
Press Room - Sanofi US News
WEB3 days ago · Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA. Read more. Sep 13, 2024.
Sanofi CEO believes company poised for growth from new drugs
WEBSep 23, 2024 · NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...
Sanofi gets two bids valuing its consumer health unit at about $17 ...
WEB(Reuters) -Sanofi has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, Bloomberg News reported ...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEBBy Sriparna Roy (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly known as "smoker's ...